Ocugen first patient dosed in Phase 3 registrational trial of OCU410
Ocugen says the first patient has been dosed in its Phase 3 registrational trial of OCU410 for geographic atrophy secondary to dry age-related macular degeneration.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.